Literature DB >> 12583827

New and modified interferon alfas: preclinical and clinical data.

Paul Masci1, Ronald M Bukowski, Phillip A Patten, Blaire L Osborn, Ernest C Borden.   

Abstract

Recombinant human interferon (IFN)-alpha was the first biotherapeutic agent approved by the US Food and Drug Administration for the treatment of a human malignancy. Its efficacy has also been demonstrated for treatment of several viral diseases. The human genome codes for 12 IFN-alpha proteins, with IFN alpha-1 and IFN alpha-2 accounting for the majority of the naturally occurring IFN-as. However, only subspecies of IFN alpha-2, recombinant human IFN alpha-2a and IFN alpha-2b, are commercially available in the United States. Other species of IFN-a may demonstrate equivalent or improved efficacy and have more tolerable side effects. This article describes ongoing preclinical and clinical studies of several new and modified IFN-alphas. A current phase I trial of a human recombinant IFN alpha-1 is described. Basic pharmacokinetics and clinical studies of polyethylene glycol (PEG) IFN alpha-2b are reviewed as well. Lastly, two novel types of IFN-a, one gene shuffled and one hybridized with human albumin, are summarized.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12583827     DOI： 10.1007/s11912-003-0097-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  12 in total

1.  Evolution of a cytokine using DNA family shuffling.

Authors:  C C Chang; T T Chen; B W Cox; G N Dawes; W P Stemmer; J Punnonen; P A Patten
Journal:  Nat Biotechnol       Date:  1999-08       Impact factor: 54.908

Review 2.  Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins.

Authors:  A L Kurtzman; S Govindarajan; K Vahle; J T Jones; V Heinrichs; P A Patten
Journal:  Curr Opin Biotechnol       Date:  2001-08       Impact factor: 9.740

3.  A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

Authors:  K L Lindsay; C Trepo; T Heintges; M L Shiffman; S C Gordon; J C Hoefs; E R Schiff; Z D Goodman; M Laughlin; R Yao; J K Albrecht
Journal:  Hepatology       Date:  2001-08       Impact factor: 17.425

4.  Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys.

Authors:  Blaire L Osborn; Henrik S Olsen; Bernardetta Nardelli; James H Murray; Joe X H Zhou; Andrew Garcia; Gordon Moody; Liubov S Zaritskaya; Cynthia Sung
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

5.  Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C.

Authors:  P Bailon; A Palleroni; C A Schaffer; C L Spence; W J Fung; J E Porter; G K Ehrlich; W Pan; Z X Xu; M W Modi; A Farid; W Berthold; M Graves
Journal:  Bioconjug Chem       Date:  2001 Mar-Apr       Impact factor: 4.774

6.  Identification of the major positional isomer of pegylated interferon alpha-2b.

Authors:  Y S Wang; S Youngster; J Bausch; R Zhang; C McNemar; D F Wyss
Journal:  Biochemistry       Date:  2000-09-05       Impact factor: 3.162

7.  Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.

Authors:  M Talpaz; S O'Brien; E Rose; S Gupta; J Shan; J Cortes; F J Giles; S Faderl; H M Kantarjian
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

Review 8.  Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.

Authors:  Ronald M Bukowski; Craig Tendler; David Cutler; Esther Rose; Mark M Laughlin; Paul Statkevich
Journal:  Cancer       Date:  2002-07-15       Impact factor: 6.860

9.  Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans.

Authors:  M J Hawkins; E C Borden; J A Merritt; B S Edwards; L A Ball; E Grossbard; K J Simon
Journal:  J Clin Oncol       Date:  1984-03       Impact factor: 44.544

10.  Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

Authors:  Ronald Bukowski; Marc S Ernstoff; Martin E Gore; John J Nemunaitis; Robert Amato; Samir K Gupta; Craig L Tendler
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544
View more
  5 in total

Review 1.  Hepatitis B and C.

Authors:  Wikrom Karnsakul; Kathleen B Schwarz
Journal:  Pediatr Clin North Am       Date:  2017-06       Impact factor: 3.278

Review 2.  Preclinical safety testing of biotechnology-derived pharmaceuticals: understanding the issues and addressing the challenges.

Authors:  Frank R Brennan; Leigh Shaw; Mark G Wing; Christine Robinson
Journal:  Mol Biotechnol       Date:  2004-05       Impact factor: 2.860

3.  Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors.

Authors:  Aung Naing; James M Reuben; Luis H Camacho; Hui Gao; Bang-Ning Lee; Evan N Cohen; Claire Verschraegen; Saneese Stephen; Joann Aaron; David Hong; Jennifer Wheler; Razelle Kurzrock
Journal:  J Cancer       Date:  2011-02-10       Impact factor: 4.207

4.  Efficient co-expression of bicistronic proteins in mesenchymal stem cells by development and optimization of a multifunctional plasmid.

Authors:  Christopher D Krause; Lara S Izotova; Gwangwen Ren; Zeng-Rong Yuan; Yufang Shi; Chiann-Chyi Chen; Yacov Ron; Sidney Pestka
Journal:  Stem Cell Res Ther       Date:  2011-03-14       Impact factor: 6.832

5.  Managing pediatric hepatitis C: current and emerging treatment options.

Authors:  Wikrom Karnsakul; Mary Kay Alford; Kathleen B Schwarz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.